Evidence map›Paper›PMID 39892937›Full record

ReviewClinics in laboratory medicine2025

Carbapenemase Mechanism Testing to Support Treatment, Infection Control, and Public Health: The Role of the Clinical Laboratory.

Sara J Blosser, Amelia S Bhatnagar, Susan Bollinger, Samantha R Giffen

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinics in laboratory medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sara J BlosserDivision of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA; Goldbelt Professional Services, LLC, Chesapeake, VA, USA. Electronic address: uno2@cdc.gov.
Amelia S BhatnagarDivision of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Susan BollingerDivision of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Samantha R GiffenDivision of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

Carbapenemase mechanism testing in carbapenem-resistant Enterobacterales is essential for informing patient treatment, infection prevention, and control. By highlighting the clinical and infection control imperative for this testing, addressing current barriers, and delineating future needs, we set the stage and advocate for routine carbapenemase mechanism testing in all clinical laboratories in the United States.

Indexed as

Bacterial Proteinsbeta-LactamasesCarbapenem-Resistant EnterobacteriaceaeEnterobacteriaceae InfectionsInfection ControlLaboratories, ClinicalAnti-Bacterial AgentsCarbapenemsHumansPublic HealthAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasescarbapenemaseCarbapenemsAntibiotic resistanceBeta-lactamase inhibitorsCarbapenemaseClinical laboratoryCRE

Identifiers

PMID39892937
PMCPMC12338270

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.